Patent foramen ovale closure and medical treatments for secondary stroke prevention

A systematic review of observational and randomized evidence

Georgios D. Kitsios, Issa J. Dahabreh, Abd Moain Abu Dabrh, David E. Thaler, David M. Kent

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

Background and Purpose-: Patients discovered to have a patent foramen ovale in the setting of a cryptogenic stroke may be treated with percutaneous closure, antiplatelet therapy, or anticoagulants. A recent randomized trial (CLOSURE I) did not detect any benefit of closure over medical treatment alone; the optimal medical therapy is also unknown. We synthesized the available evidence on secondary stroke prevention in patients with patent foramen ovale and cryptogenic stroke. Methods-: A MEDLINE search was performed for finding longitudinal studies investigating medical treatment or closure, meta-analysis of incidence rates (IR), and IR ratios of recurrent cerebrovascular events. Results-: Fifty-two single-arm studies and 7 comparative nonrandomized studies and the CLOSURE I trial were reviewed. The summary IR of recurrent stroke was 0.36 events (95% confidence interval [CI], 0.24-0.56) per 100 person-years with closure versus 2.53 events (95% CI, 1.91-3.35) per 100 person-years with medical therapy. In comparative observational studies, closure was superior to medical therapy (IR ratio=0.19; 95% CI, 0.07-0.54). The IR for the closure arm of the CLOSURE I trial was higher than the summary estimate from observational studies; there was no significant benefit of closure over medical treatment (P=0.002 comparing efficacy estimates between observational studies and the trial). Observational and randomized data (9 studies) comparing medical therapies were consistent and suggested that anticoagulants are superior to antiplatelets for preventing stroke recurrence (IR ratio=0.42; 95% CI, 0.18-0.98). Conclusions-: Although further randomized trial data are needed to precisely determine the effects of closure on stroke recurrence, the Results of CLOSURE I challenge the credibility of a substantial body of observational evidence strongly favoring mechanical closure over medical therapy.

Original languageEnglish (US)
Pages (from-to)422-431
Number of pages10
JournalStroke
Volume43
Issue number2
DOIs
StatePublished - Feb 1 2012
Externally publishedYes

Fingerprint

Patent Foramen Ovale
Secondary Prevention
Stroke
Incidence
Confidence Intervals
Observational Studies
Therapeutics
Anticoagulants
Recurrence
MEDLINE
Longitudinal Studies
Meta-Analysis

Keywords

  • meta-analysis
  • observational studies
  • patent foramen ovale
  • stroke

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialized Nursing

Cite this

Patent foramen ovale closure and medical treatments for secondary stroke prevention : A systematic review of observational and randomized evidence. / Kitsios, Georgios D.; Dahabreh, Issa J.; Abu Dabrh, Abd Moain; Thaler, David E.; Kent, David M.

In: Stroke, Vol. 43, No. 2, 01.02.2012, p. 422-431.

Research output: Contribution to journalArticle

Kitsios, Georgios D. ; Dahabreh, Issa J. ; Abu Dabrh, Abd Moain ; Thaler, David E. ; Kent, David M. / Patent foramen ovale closure and medical treatments for secondary stroke prevention : A systematic review of observational and randomized evidence. In: Stroke. 2012 ; Vol. 43, No. 2. pp. 422-431.
@article{29fbe18800304be584bad30554213281,
title = "Patent foramen ovale closure and medical treatments for secondary stroke prevention: A systematic review of observational and randomized evidence",
abstract = "Background and Purpose-: Patients discovered to have a patent foramen ovale in the setting of a cryptogenic stroke may be treated with percutaneous closure, antiplatelet therapy, or anticoagulants. A recent randomized trial (CLOSURE I) did not detect any benefit of closure over medical treatment alone; the optimal medical therapy is also unknown. We synthesized the available evidence on secondary stroke prevention in patients with patent foramen ovale and cryptogenic stroke. Methods-: A MEDLINE search was performed for finding longitudinal studies investigating medical treatment or closure, meta-analysis of incidence rates (IR), and IR ratios of recurrent cerebrovascular events. Results-: Fifty-two single-arm studies and 7 comparative nonrandomized studies and the CLOSURE I trial were reviewed. The summary IR of recurrent stroke was 0.36 events (95{\%} confidence interval [CI], 0.24-0.56) per 100 person-years with closure versus 2.53 events (95{\%} CI, 1.91-3.35) per 100 person-years with medical therapy. In comparative observational studies, closure was superior to medical therapy (IR ratio=0.19; 95{\%} CI, 0.07-0.54). The IR for the closure arm of the CLOSURE I trial was higher than the summary estimate from observational studies; there was no significant benefit of closure over medical treatment (P=0.002 comparing efficacy estimates between observational studies and the trial). Observational and randomized data (9 studies) comparing medical therapies were consistent and suggested that anticoagulants are superior to antiplatelets for preventing stroke recurrence (IR ratio=0.42; 95{\%} CI, 0.18-0.98). Conclusions-: Although further randomized trial data are needed to precisely determine the effects of closure on stroke recurrence, the Results of CLOSURE I challenge the credibility of a substantial body of observational evidence strongly favoring mechanical closure over medical therapy.",
keywords = "meta-analysis, observational studies, patent foramen ovale, stroke",
author = "Kitsios, {Georgios D.} and Dahabreh, {Issa J.} and {Abu Dabrh}, {Abd Moain} and Thaler, {David E.} and Kent, {David M.}",
year = "2012",
month = "2",
day = "1",
doi = "10.1161/STROKEAHA.111.631648",
language = "English (US)",
volume = "43",
pages = "422--431",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Patent foramen ovale closure and medical treatments for secondary stroke prevention

T2 - A systematic review of observational and randomized evidence

AU - Kitsios, Georgios D.

AU - Dahabreh, Issa J.

AU - Abu Dabrh, Abd Moain

AU - Thaler, David E.

AU - Kent, David M.

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Background and Purpose-: Patients discovered to have a patent foramen ovale in the setting of a cryptogenic stroke may be treated with percutaneous closure, antiplatelet therapy, or anticoagulants. A recent randomized trial (CLOSURE I) did not detect any benefit of closure over medical treatment alone; the optimal medical therapy is also unknown. We synthesized the available evidence on secondary stroke prevention in patients with patent foramen ovale and cryptogenic stroke. Methods-: A MEDLINE search was performed for finding longitudinal studies investigating medical treatment or closure, meta-analysis of incidence rates (IR), and IR ratios of recurrent cerebrovascular events. Results-: Fifty-two single-arm studies and 7 comparative nonrandomized studies and the CLOSURE I trial were reviewed. The summary IR of recurrent stroke was 0.36 events (95% confidence interval [CI], 0.24-0.56) per 100 person-years with closure versus 2.53 events (95% CI, 1.91-3.35) per 100 person-years with medical therapy. In comparative observational studies, closure was superior to medical therapy (IR ratio=0.19; 95% CI, 0.07-0.54). The IR for the closure arm of the CLOSURE I trial was higher than the summary estimate from observational studies; there was no significant benefit of closure over medical treatment (P=0.002 comparing efficacy estimates between observational studies and the trial). Observational and randomized data (9 studies) comparing medical therapies were consistent and suggested that anticoagulants are superior to antiplatelets for preventing stroke recurrence (IR ratio=0.42; 95% CI, 0.18-0.98). Conclusions-: Although further randomized trial data are needed to precisely determine the effects of closure on stroke recurrence, the Results of CLOSURE I challenge the credibility of a substantial body of observational evidence strongly favoring mechanical closure over medical therapy.

AB - Background and Purpose-: Patients discovered to have a patent foramen ovale in the setting of a cryptogenic stroke may be treated with percutaneous closure, antiplatelet therapy, or anticoagulants. A recent randomized trial (CLOSURE I) did not detect any benefit of closure over medical treatment alone; the optimal medical therapy is also unknown. We synthesized the available evidence on secondary stroke prevention in patients with patent foramen ovale and cryptogenic stroke. Methods-: A MEDLINE search was performed for finding longitudinal studies investigating medical treatment or closure, meta-analysis of incidence rates (IR), and IR ratios of recurrent cerebrovascular events. Results-: Fifty-two single-arm studies and 7 comparative nonrandomized studies and the CLOSURE I trial were reviewed. The summary IR of recurrent stroke was 0.36 events (95% confidence interval [CI], 0.24-0.56) per 100 person-years with closure versus 2.53 events (95% CI, 1.91-3.35) per 100 person-years with medical therapy. In comparative observational studies, closure was superior to medical therapy (IR ratio=0.19; 95% CI, 0.07-0.54). The IR for the closure arm of the CLOSURE I trial was higher than the summary estimate from observational studies; there was no significant benefit of closure over medical treatment (P=0.002 comparing efficacy estimates between observational studies and the trial). Observational and randomized data (9 studies) comparing medical therapies were consistent and suggested that anticoagulants are superior to antiplatelets for preventing stroke recurrence (IR ratio=0.42; 95% CI, 0.18-0.98). Conclusions-: Although further randomized trial data are needed to precisely determine the effects of closure on stroke recurrence, the Results of CLOSURE I challenge the credibility of a substantial body of observational evidence strongly favoring mechanical closure over medical therapy.

KW - meta-analysis

KW - observational studies

KW - patent foramen ovale

KW - stroke

UR - http://www.scopus.com/inward/record.url?scp=84856440512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856440512&partnerID=8YFLogxK

U2 - 10.1161/STROKEAHA.111.631648

DO - 10.1161/STROKEAHA.111.631648

M3 - Article

VL - 43

SP - 422

EP - 431

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 2

ER -